COMPARING EFFECTIVENESS OF CAPSULE SILYMARIN WITH THAT OF SM FIBRO CAPSULE IN THE MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS
Phase 4
- Conditions
- Health Condition 1: - Health Condition 2: - Health Condition 3: K135- Oral submucous fibrosis
- Registration Number
- CTRI/2024/01/061326
- Lead Sponsor
- KAKARLA VENKATA SUSMITHA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed OSMF ( stage 1,2 & 3 as per the criteria put forward by the Tinky Bose and Anitha Balan.
Patients who are ready to quit the habit
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method INCREASE IN MOUTH OPENINGTimepoint: AT A BASELINE OF 8 WEEKS
- Secondary Outcome Measures
Name Time Method DECREASE IN FURTHER PROGRESSION <br/ ><br> OF CONDITIONTimepoint: 8 WEEKS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Silymarin's anti-fibrotic effects in oral submucous fibrosis compared to lycopene-alpha lipoic acid-tocopherol combinations?
How does Silymarin's efficacy in reducing collagen deposition in OSMF compare to standard antioxidant therapies like SM Fibro Capsule?
Which biomarkers (e.g., TGF-β, Nrf2) correlate with treatment response to Silymarin versus lycopene-based regimens in OSMF patients?
What are the safety profiles and adverse event management strategies for Silymarin and SM Fibro Capsule in chronic OSMF treatment?
What alternative natural compounds or drug combinations show promise in targeting oxidative stress pathways for OSMF management alongside CTRI/2024/01/061326?